Pay in 4 interest-free payments of $6.75 Learn more
Ships within 48 hours · Estimated delivery Sep 1 - Sep 6
(2011) demonstrated enhanced cell survival, migration, and outgrowth in vitro and in vivo
Evaluation: Body fat (DXA scanning) Lean mass Insulin sensitivity Energy expenditure What they found: The combination showed an additive effect on fat reduction vs monotherapy AOD-9604 partially protected lean mass during GLP-1-induced weight reduction Increased energy expenditure in combination (~3 % vs GLP-1 alone) No new safety signals Why it matters: It validates the concept of combination , the idea that AOD-9604 may not work on its own, but can add value in combination with incretin agonists
Used as an adjunct in metabolic, neurological, and longevity-focused protocols
Corporate Medical United States | Change English | Espaol Contact Us Shop Supplies | Solutions & Services | Discover Henry Schein Because So Many Rely on You
US$ 27.16
US$ 22.47
US$ 25.11
US$ 28.79
